Skip to main content
SpringerLink
Log in

Place de la tomographie à émission de positons (TEP-TDM) dans les cancers du sein: données actuelles et perspectives

  • Conference paper
Cancer du sein

  • 273 Accesses

Abstrait

Les techniques sont hétérogènes au fil des années de publication et la localisation anatomique précise s’est considérablement améliorée grâce au couplage de la tomographie à émission de positons avec la tomodensitométrie et au développement d’appareils de nouvelle génération. De plus, les systèmes de détection plus performants au cours des années ont permis une progressive et importante amélioration de la résolution de ces systèmes de détection ayant évouée de 17 mm à actuellement 7 à 5 mm.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NL, Shenk RR (1997) Axillary lymph node metastases: screening with2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 203: 323–327

    PubMed  CAS  Google Scholar 

  2. Avril N, Dose J, Janicke F et al. (1996) Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Nat Cancer Inst 88: 1204–1209

    Article  PubMed  CAS  Google Scholar 

  3. Bender H, Kirst J, Palmedo H et al. (1997) Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 17: 1687–1692

    PubMed  CAS  Google Scholar 

  4. Bourguet P, Hitzel A, Houvenaeghel G, Vinatier D, Bosquet L (2006) 2005 monitoring report: use of positron emission tomography with fluorodeoxyglucose in the management of patients with breast cancer, ovarian cancer, and uterine cancer. Gynécol Obst Fertil 34: 437–459

    Article  CAS  Google Scholar 

  5. Bourguet P, Hitzel A, Houvenaeghel G et al. (2006) Bulletin de synthèse de veille 2005. Recommandations pour la pratique clinique: Mise à jour 2005 des recommandations pour la prise en charge des patients adultes atteints d’un mélanome cutané sans métastase à distance. Bull Cancer 93: 385–390

    PubMed  CAS  Google Scholar 

  6. Chaiken L, Rege S, Höh C et al. (1993) Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Intern J Rad Oncol Biol Physics 27: 455–464

    CAS  Google Scholar 

  7. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I (1998) Detection of bone métastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16: 3375–3379

    PubMed  CAS  Google Scholar 

  8. Danforth DN Jr, Aloj L, Carrasquillo JA et al. (2002) The role of 18F-FDGPET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat 75: 135–146

    Article  PubMed  CAS  Google Scholar 

  9. Dose J, Bleckmann C, Bachmann S et al. (2002) Comparison of fluorodeoxyglucose positron emission tomography and “conventional diagnostic procedures” for the detection of distant métastases in breast cancer patients. Nucl Med Commun 23: 857–864

    Article  PubMed  CAS  Google Scholar 

  10. Eubank WB, Mankoff DA, Takasugi J et al. (2001) 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 19: 3516–3523

    PubMed  CAS  Google Scholar 

  11. Eubank WB, Mankoff D, Bhattacharya M et al. (2004) Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. Am J Roentgenol 183: 479–486

    Google Scholar 

  12. Gallowitsch HJ, Kresnik E, Gasser J et al. (2003) F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 38: 250–256

    Article  PubMed  Google Scholar 

  13. Gil-Rendo A, Zornoza G, Garcia-Velloso MJ et al. (2006) Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 93: 707–712

    Article  PubMed  CAS  Google Scholar 

  14. Goerres GW, Michel SC, Fehr MK et al. (2003) Follow-up of women with breast cancer: comparison between MRI and FDG PET. Eur Radiol 13: 1635–1644

    Article  PubMed  Google Scholar 

  15. Greco M, Crippa F, Agresti R et al. (2001) Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Nat Cancer Inst 93: 630–635

    Article  PubMed  CAS  Google Scholar 

  16. Guller U, Nitzsche EU, Schirp U et al. (2002) Selective axillary surgery in breast cancer patients based on positron emission tomography with 18Ffluoro-2-deoxy-D-glucose: not yet! Breast Cancer Res Treat 71: 171–173

    Article  PubMed  Google Scholar 

  17. Hathaway PB, Mankoff DA, Maravilla KR et al. (1999) Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent localregional breast cancer: preliminary experience. Radiology 210: 807–814

    PubMed  CAS  Google Scholar 

  18. Hubner KF, Thie JA, Smith GT et al. (2000) Clinical utility of FDG-PET in detecting head and neck tumor: a comparison of diagnostic methods and modalities. Clin Positron Imag 3: 7–16

    Article  Google Scholar 

  19. Inoue T, Yutani K, Taguchi T et al. (2004) Preoperative evaluation of prognosis in breast cancer patients by ((18)F)2-Deoxy-2-fluoro-D-glucose-positron emission tomography. J Cancer Res Clin Oncol 130: 273–278

    Article  PubMed  Google Scholar 

  20. Jansson T, Westlin JE, Ahlstrom H et al. (1995) Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 13: 1470–1477

    PubMed  CAS  Google Scholar 

  21. Kamel EM, Wyss MT, Fehr MK et al. (2003) Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 129: 147–153

    PubMed  Google Scholar 

  22. Kim TS, Moon WK, Lee DS et al. (2001) Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg 25: 829–834

    Article  PubMed  CAS  Google Scholar 

  23. Kim SJ, Kim SK, Lee ES, Ro J, Kang S (2004) Predictive value of (18F)FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 15: 1352–1357

    Article  PubMed  Google Scholar 

  24. Lin WC, Hung YC, Yeh LS et al. (2003) Usefulness of (18)F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings. Gynecol Oncol 89: 73–76

    Article  PubMed  Google Scholar 

  25. Liu CS, Shen YY, Lin CC et al. (2002) Clinical impact of ((18)F)FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report. Jpn J Clin Oncol 32: 244–247

    Article  PubMed  Google Scholar 

  26. Lonneux M, Lawson G, Ide C et al. (2000) Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope 110: 1493–1497

    Article  PubMed  CAS  Google Scholar 

  27. Moon DH, Maddahi J, Silverman DH et al. (1998) Accuracy of whole-body fluorine18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 39: 431–435

    PubMed  CAS  Google Scholar 

  28. Mortimer JE, Dehdashti F, Siegel BA et al. (1996) Positron emission tomography with 2-Fluoro-2-deoxy-D-glucose and 16alpha-fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 2: 933–939

    PubMed  CAS  Google Scholar 

  29. Ohta M, Tokuda Y, Suzuki Y et al. (2001) Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99TcmMDP bone scintigraphy. Nucl Med Comm 22: 875–879

    Article  CAS  Google Scholar 

  30. Pecking AP, Méchélany-Corone C, Bertrand-Kermogant F et al. (2001) Detection of occult disease in breast cancer using fluorodeoxyglucose camera based positron emission tomography. Clin Breast Cancer 2: 229–234

    Article  PubMed  CAS  Google Scholar 

  31. Rostom AY, Powe J, Kandil A et al. (1999) Positron emission tomography in breast cancer: a clinicopathological correlation of results. Br J Radiol 72: 1064–1068

    PubMed  CAS  Google Scholar 

  32. Rousseau C, Devillers A, Sagan C et al. (2006) Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by (18 F) Fluorodeoxyglucose positron emission tomography. J Clin Oncol 24: 5366–5372

    Article  PubMed  Google Scholar 

  33. Samson DJ, Flamm CR, Pisano ED, Aronson N (2002) Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy? Acad Radiol 9: 773–783

    Article  PubMed  Google Scholar 

  34. Schelling M, Avril N, Nahrig J et al. (2000) Positron emission tomography usingFluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18: 1689–1695

    PubMed  CAS  Google Scholar 

  35. Schirrmeister H, Kuhn T, Guhlmann A et al. (2001) Fluorine-18-2-deoxy-2fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. European J Nucl Med 28: 351–358

    Article  CAS  Google Scholar 

  36. Siggelkow W, Zimny M, Faridi A et al. (2003) The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res 23: 1859–1867

    PubMed  Google Scholar 

  37. Smith IC, Ogston KN, Whitford P et al. (1998) Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 228: 220–227

    Article  PubMed  CAS  Google Scholar 

  38. Smith IC, Welch AE, Hutcheon AW et al. (2000) Positron emission tomography using-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18: 1676–1688

    PubMed  CAS  Google Scholar 

  39. Suarez M, Perez-Castejon MJ, Jimenez A et al. (2002) Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 46: 113–121

    PubMed  CAS  Google Scholar 

  40. Tofighi M, Tamgac F, Weinmann P et al. (2002) Augmentation de ca 15-3 dans le suivi du cancer du sein: Recherche de récidive par ((18)F)-Fdg et tomographie d’émission par détection de coïncidence tedc. ((18)F)-FDG coincidence imaging in patients with increased CA 15-3 levels during followup for breast cancer. Med Nucl 26: 87–94

    Google Scholar 

  41. Utech CI, Young CS, Winter PF (1996) Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. European J Nucl Med 23: 1588–1593

    Article  CAS  Google Scholar 

  42. Van der Hoeven JJ, Krak NC, Hoekstra OS et al. (2004) 18F-2-fluoro-2deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer. J Clin Oncol 22: 1253–1259

    Article  PubMed  CAS  Google Scholar 

  43. Wahl RL, Zasadny K, Helvie M et al. (1993) Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 11: 2101–2111

    PubMed  CAS  Google Scholar 

  44. Yang SN, Liang JA, Lin FJ et al. (2002) Comparing whole body (18)F-2deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 128: 325–328

    Article  PubMed  CAS  Google Scholar 

  45. Yap CS, Seltzer MA, Schiepers C et al. (2001) Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician’s perspective. J Nucl Med 42: 1334–1337

    PubMed  CAS  Google Scholar 

  46. Zornoza G, Garcia-Velloso MJ, Sola J et al. (2004) 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol 30: 15–19

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut Paoli-Calmettes, 232, bd Sainte-Marguerite, 13273, Marseille cedex 9

    G. Houvenaeghel

Authors
  1. G. Houvenaeghel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag France, Paris

About this paper

Cite this paper

Houvenaeghel, G. (2007). Place de la tomographie à émission de positons (TEP-TDM) dans les cancers du sein: données actuelles et perspectives. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/978-2-287-71478-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-71478-8_12

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-71477-1

  • Online ISBN: 978-2-287-71478-8

Publish with us

Policies and ethics

Search

Navigation